Skip to main content

Table 3 sPSA detection rate in post-menopausal breast cancer patients (n = 117)

From: Clinical significance of serum PSA in breast cancer patients

  n sPSA positive (%) sPSA negative (%) p value
Clinical stage 0.0072
 Non-MBC; Stage 0-III 45 6 (13.3) 39 (86.7)  
 MBC; Stage VI, Recurrence 72 26 (36.1) 46 (63.9)
Histological type 0.9320
 Invasive ductal carcinoma 82 21 (25.6) 61 (74.4)  
 Ductal carcinoma in situ 6 2 (33.3) 4 (66.7)
 Invasive lobular carcinoma 10 3 (30.0) 7 (70.0)
 Special type 19 6 (31.6) 13 (68.4)
Subtype 0.3028
 Luminal; ER+ / HER2- 83 19 (22.9) 64 (77.1)  
 Luminal HER2; ER+ / HER2+ 13 6 (46.2) 7 (53.8)
 HER2 enriched; ER- / HER2+ 7 2 (28.6) 5 (71.4)
 TNBC; ER- / HER2- 14 5 (35.7) 9 (64.3)
Androgen receptor 0.0034
  < 20% 55 8 (14.5) 47 (85.5)  
  ≥ 20% 59 23 (39.0) 36 (61.0)
 Unknown 3 1 (33.3) 2 (66.7)
PSA (IHC of primary lesion) 0.1271
 Positive 64 21 (32.8) 43 (67.2)  
 Negative 50 10 (20.0) 40 (80.0)
 Unknown 3 1 (33.3) 2 (66.7)
Nuclear grade 0.7405
 1 67 18 (26.9) 49 (73.1)  
 2 36 9 (25.0) 27 (75.0)
 3 14 5 (35.7) 9 (64.3)
Ki67 (LI) 0.0400
  < 20% 52 19 (36.5) 33 (63.5)  
  ≥ 20% 62 12 (19.4) 50 (80.6)
 Unknown 3 1 (33.3) 2 (66.7)
\